| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aquestive Therapeutics, Inc. (AQST) has 17 insiders with recent SEC Form 4 filings, including 2 buys and 0 sells. AQST is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 660.6K | $3.11M | - | |
| Other | 366.7K | $1.73M | - | |
| CFO | 283.5K | $1.34M | - | |
| Other | 282.5K | $1.33M | - | |
| Other | 281.7K | $1.33M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2018 | Marshall Ken W. | Commercial Leader | Buy | 1,445 | $10.15 | $14,666.75 | New | |
| Jul 24, 2018 | Bratton Douglas K | Director, 10% Owner | Buy | 165,000 | $15.00 | $2,475,000.00 | New |